10 updates for World Thrombosis Day
Oct. 13 is World Thrombosis Day, part of a campaign to raise awareness about the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.
In conjunction with the annual observance, now in its fifth year, HemOnc Today highlights nine research updates in thrombosis treatment, surveillance and risk prediction.
- A $4.7 million grant from the NHLBI will support a Cleveland Clinic-led research consortium’s effort to develop a better risk-prediction tool for cancer-associated venous thromboembolism. READ MORE.
- Patients with deep vein thrombosis who underwent immediate compression therapy had significantly lower rates of residual vein obstruction and post-thrombotic syndrome than those who received no compression. READ MORE.
- Extended thromboprophylaxis with weight-adjusted tinzaparin appeared safe and effective for patients following bariatric surgery. Patients experienced few incidences of VTE and major bleeding. READ MORE.
- Outpatient treatment appeared safe for select patients with acute pulmonary embolism with low risk for mortality. No deaths or recurrent VTE occurred among patients treated at home. READ MORE.
- Patients with moderate-to-severe liver disease demonstrated a lower risk for VTE compared with those without liver disease. However, those with moderate-severe liver disease who developed VTE had an increased risk for in-hospital mortality. READ MORE.
- Women with VTE demonstrated an acute decrease in physical function compared with women without VTE. READ MORE.
- Compression hosiery improved quality of life and appeared cost-effective for the acute phase between diagnosis of DVT and application of elastic compression stockings. READ MORE.
- Although multilayer bandaging appeared slightly more effective than hosiery, it cost significantly more and did not improve quality of life. READ MORE.
- Perioperative red blood cell transfusions appeared associated with new or progressive VTE in the postoperative setting. READ MORE.
- Rivaroxaban (Xarelto, Janssen) increased risk for cardiac events compared with warfarin among patients with high-risk antiphospholipid syndrome. READ MORE.